A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis | AVESİS

Karadeniz Teknik Üniversitesi Akademik Veri Yönetim Sistemi

A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis

Atıf İçin Kopyala

Spelman T., Havrdova E., Horakova D., Trojano M., Lugaresi A., Izquierdo G., ...Daha Fazla

70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90

Yayın Türü: Bildiri / Özet Bildiri
Cilt numarası: 90
Basıldığı Şehir: Los-Angeles
Basıldığı Ülke: Şili
Karadeniz Teknik Üniversitesi Adresli: Evet